Gender-Based and Age-Related Peculiarities of Lipid Metabolism in Chronic Heart Failure Secondary to Overweight and Obesity

  • P. P. Bidzilya Zaporizhzhya State Medical University, Zaporizhzhya
Keywords: heart failure, lipid metabolism, overweight, gender, age


Chronic heart failure is often accompanied by comorbidities including obesity being the major one. It significantly aggravates the course of the disease and clinical outcome. Changes in the plasma concentration of lipids in chronic heart failure were demonstrated by many studies. Recently a considerable number of works has appeared in which a negative influence of both high and low levels of lipids on the course, consequences and survival in patients with chronic heart failure was observed.

            The objective of the research was to study gender-based and age-related peculiarities of lipid metabolism in chronic heart failure secondary to overweight and obesity.

            Material and methods. There were examined 212 patients with chronic heart failure functional class I-III having normal body weight, I-III degree abdominal obesity or being overweight. Patients underwent complete blood count and biochemical blood analysis; instrumental examination was performed according to the existing guidelines for the diagnosis and treatment of chronic heart failure. Statistical processing of the obtained material was performed using an advanced analytics software package Statistica 6.0.

            Results and discussion. Both atherogenic and antiatherogenic components of lipid metabolism predominated in females. Age-related changes were presented by higher levels of atherogenic indices and prevalence of dyslipidemia in young patients reducing with age in parallel with the deepening of chronic heart failure.


Voronkov LH, et al. Guidelines for the diagnosis and treatment of chronic heart failure (2012). Ukrainskiy kardiologicheskiy zhurnal. 2013;1:6–44.

Kravchun PP. The role of lipid metabolism in the pathogenesis of CHF in patients with post-infarction cardiosclerosis, diabetes mellitus type 2 and obesity. Odeskyi medychnyi zhurnal. 2015;1(147):41-44.

AHA Scientific Statement. Prevention of heart failure. Circulation. 2008;117:2544–2565.

Charach G, George J, Roth A, et al. Baseline Low-Density Lipoprotein Cholesterol Levels and Outcome in Patients with Heart Failure. Am. J. Cardiol. 2010;105:100-104. doi: 10.1016/j.amjcard.2009.08.660.

Charach G, George J. LDL- Cholesterol and Outcome Prediction in Patients with Congestive Heart Failure. J. Cardiol. Curr. Res. 2014;1(2):100-107. doi: 10.15406/jccr.2014.01.00007

Domanski M, Coady S, Fleg J, et al. Effect of statin therapy on survival in patients with non-ischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]). Am. J. Cardiol. 2007;99:1448-1450.

Raina A, Pickering T, Shimbo D. Statin use in heart failure: a cause for concern? Am. Heart J. 2006;152:39-49.

Sakatani T, Shirayama T, Suzaki Y, et al. The association between cholesterol and mortality in heart failure. Comparison between patients with and without coronary artery disease. Int. Heart J. 2005;46:619-629.

Strandberg TE. Lipid-lowering drugs and heart failure: where do we go after the statin trials? Current Opinion in Cardiology. 2010;25:385-393.

Tousoulis D, Charakida M, Stefanadi E, et al. Statins in heart failure. Beyond the lipid lowering effect. Int. J. Cardiol. 2007;115:144-150. doi: 10.1016/j.ijcard.2006.03.094

Velagaleti RS, Massaro J, Vasan RS, et al. Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study. Circulation. 2009;120:2345-2351. doi: 10.1161/CIRCULATIONAHA.109.830984.

Original Research